Indaptus Therapeutics (INDP) Research & Development (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Research & Development of $491134.0 for Q1 2026, down 82.53% year-over-year from $2.8 million in Q1 2025, and down 82.74% quarter-over-quarter from $2.8 million in Q4 2025.
Indaptus Therapeutics (INDP) Research & Development (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $491134.0 for Q1 2026.
- In Q1 2026, Research & Development fell 82.53% year-over-year to $491134.0; the TTM figure through Mar 2026 stood at $7.0 million (down 17.11% YoY), while the FY2025 annual figure was $9.3 million, up 28.82% from the prior year.
- Research & Development for Q1 2026 stood at $491134.0, down from $2.8 million in the prior quarter.
- The five-year high for Research & Development was $2.8 million in Q4 2025, with the low at $491134.0 in Q1 2026.
- The 5-year median for Research & Development is $1.7 million (2024), against an average of $1.8 million.
- The sharpest annual moves came in 2022 and 2026: Research & Development surged 285.09% in 2022, then slumped 82.53% in 2026.
- Indaptus Therapeutics' Research & Development stood at $1.9 million in 2022, then climbed by 6.42% to $2.0 million in 2023, then increased by 21.89% to $2.5 million in 2024, then gained by 14.73% to $2.8 million in 2025, then tumbled by 82.74% to $491134.0 in 2026.
- Business Quant data shows INDP's Research & Development at $491134.0 in Q1 2026, $2.8 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.69 Bn | 131.84 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.46 Bn | 78.47 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.62 Bn | 60.44 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.37 Bn | 53.24 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.43 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.87 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.23 Bn | 26.40 Bn | - | 97.90 Mn |
| 10 | Indaptus Therapeutics | 148.65 Mn | 137.09 Mn | - | 363,127.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 363,127.00 |
| Mar 31, 2026 | 491,134.00 |
| Dec 31, 2025 | 2.85 Mn |
| Sep 30, 2025 | 1.52 Mn |
| Jun 30, 2025 | 2.17 Mn |
| Mar 31, 2025 | 2.81 Mn |
| Dec 31, 2024 | 2.48 Mn |
| Sep 30, 2024 | 1.47 Mn |
| Jun 30, 2024 | 1.71 Mn |
| Mar 31, 2024 | 1.59 Mn |
| Dec 31, 2023 | 2.03 Mn |
| Sep 30, 2023 | 2.23 Mn |
| Jun 30, 2023 | 1.48 Mn |
| Mar 31, 2023 | 1.88 Mn |
| Dec 31, 2022 | 1.91 Mn |
| Sep 30, 2022 | 1.61 Mn |
| Jun 30, 2022 | 1.51 Mn |
| Mar 31, 2022 | 1.30 Mn |
| Dec 31, 2021 | 944,641.00 |
| Sep 30, 2021 | 697,674.00 |